Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Financings Routine −

Medicenna Announces the Finalization of the Terms of its Public Offering of Securities

Financing Finalized at Discount as Dilution Concerns Weigh on Stock

By The Northwire Desk — AI Analysis May 19, 2026 · 07:00 MDNA · 0.54 MEDICENNA THERAPEUTICS CORP. J
Executive Summary
  • Medicenna Therapeutics has finalized terms for a public offering of units priced at $0.50 per unit.
  • Each unit consists of one common share and one-half warrant with an exercise price of $0.65 expiring in three years.
  • The offering is underwritten by Bloom Burton Securities Inc., expected to close around May 27, 2026.
  • Proceeds are designated for clinical/regulatory development of MDNA11 and MDNA113, working capital, and general corporate purposes.
  • This follows the launch announcement on May 13, 2026, which was priced as a best-efforts marketed offering.
Material Impact
  • The financing is dilutive to existing shareholders given the $0.50 offering price against recent trading levels near $0.60-$0.66 prior to finalization.
  • While essential for extending cash runway beyond Q3 2026, the discount pricing signals market pressure and lack of premium valuation support.
  • The terms are consistent with previous announcements (May 13), making this a follow-up event rather than new information.
  • Dilution risk is immediate upon closing, likely suppressing stock price momentum despite clinical progress.
MDNA · Price
Company Overview
  • Medicenna Therapeutics develops immunotherapy assets focused on IL-2 Superkines and bifunctional proteins.
  • Flagship asset MDNA11 is a long-acting "beta-enhanced not-alpha" IL-2 Superkine currently in Phase 1/2 ABILITY-1 trial for advanced solid tumors.
  • MDNA113 is a first-in-class tumor-anchored anti-PD-1 x IL-2 bifunctional protein advancing toward IND submission.
  • Bizaxofusp (MDNA55) targets recurrent glioblastoma with Phase 2b data showing improved overall survival compared to standard care.
Read the original news release →

More from MEDICENNA THERAPEUTICS CORP. J

Jun 26, 2026 · 08:45

Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights

Earnings Jun 11, 2026 · 07:00

Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms

M&A / Property Jun 03, 2026 · 07:00

ASCO Presentation Offers No New Catalysts as Dilutive Capital Raise Extends Runway Amid Steep Equity Erosion

Other May 28, 2026 · 09:10

Medicenna Secures $12.4M Lifeline Amidst Dilution Concerns and Clinical Milestones

Financings May 22, 2026 · 07:00

Medicenna Files $13M Financing at Deep Discount as Cash Dwindles and Stock Spirals

Financings May 13, 2026 · 16:01

Cash Runway Expiry Triggers Dilutive Financing Despite Clinical Milestones

Financings